Does Mississippi Medicaid Cover Wegovy? Prior Authorization and Costs

Yes, Mississippi Medicaid does cover Wegovy for weight loss. The drug has been on the state’s preferred drug list since July 2023 for enrollees aged 12 and older, but every prescription requires manual prior authorization, and keeping the coverage past the first six months depends on documented weight loss.¹

Who Qualifies

Mississippi Medicaid lists Wegovy as a preferred anti-obesity medication alongside Saxenda (liraglutide). The clinical criteria differ by age.¹

Adults 18 and older need one of the following:

A BMI of 30 or greater, or
A BMI between 25 and 29 together with at least one weight-related comorbidity.

Qualifying comorbidities include hypertension, high cholesterol, glucose dysregulation or diabetes, obstructive sleep apnea, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease.²

Children and teens aged 12 to 17 qualify with a BMI above the 95th percentile for their age and sex, based on CDC growth charts.³

Some patients are categorically ineligible. Wegovy is not covered during pregnancy or breastfeeding, and it is not approved for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.²

How Prior Authorization Works

Your prescriber submits the request, not you. Providers can send prior authorization requests through the MESA provider portal at ms-medicaid-mesa.com or by fax to 1-866-644-6147.

The paperwork has to include your Medicaid beneficiary ID, your current BMI, weight, and height, the relevant diagnosis codes, and a written treatment plan with six-month goals. The provider also has to confirm that they counseled you on diet and physical activity. If you are qualifying under the lower BMI range of 25 to 29, the provider needs to document the specific comorbidity with supporting clinical evidence such as lab values, diagnosis codes, or claims history.³

An initial approval lasts six months.

What It Takes to Stay on Wegovy

Reauthorization is not automatic. At the six-month mark, your provider has to show three things:

You have been adherent, defined as at least three filled prescriptions in the previous 105 days.
You are tolerating a target dose of 1.7 mg or 2.4 mg per week.
You have lost weight.

The weight loss thresholds are firm. Losing 5% or more of your body weight gets you another six months. Losing between 1% and 4% may get you a three-month extension, but only if your provider documents a specific reason for the slower pace, such as dose titration problems, hospitalization, or illness. Losing less than 1% means the reauthorization is denied.²

Once you reach your goal BMI and maintain your weight within 15% of that goal, you can qualify for a 12-month maintenance authorization instead of the six-month cycle.³

What Mississippi Medicaid Won’t Cover

Only one anti-obesity medication is covered at a time. You cannot be on Wegovy and Saxenda simultaneously, and Wegovy is contraindicated with other GLP-1 receptor agonists or DPP-4 inhibitors. If you are already taking Ozempic for diabetes, you cannot add Wegovy for weight loss.²

Ozempic itself is not covered for weight loss. The state requires the Wegovy formulation for that purpose and does not allow off-label use of the diabetes version of semaglutide.⁴ Zepbound (tirzepatide), which is FDA-approved for weight loss, does not appear on Mississippi Medicaid’s preferred drug list or anti-obesity coverage list.¹

There is also no separate pathway for Wegovy’s FDA-approved cardiovascular risk reduction use. Cardiovascular disease counts only as a qualifying comorbidity under the obesity criteria, not as its own reason for approval.³

A Different Pathway for Fatty Liver Disease

Wegovy has its own prior authorization pathway for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. This pathway is only for patients with noncirrhotic MASH and moderate to advanced liver fibrosis at stages F2 to F3, and the drug has to be prescribed by or in consultation with a gastroenterologist or hepatologist.

Unlike the obesity pathway, the MASH pathway has no BMI requirement. Both the initial authorization and each reauthorization run 12 months, and renewal requires documentation of a positive clinical response such as improvement or stabilization of fibrosis.⁵

Cost Context

GLP-1 weight loss drugs typically cost around $1,000 per month at retail.⁶ When Mississippi Medicaid approves a Wegovy prior authorization, the drug is covered as a pharmacy benefit under the standard Medicaid cost-sharing rules.

Coverage can change. Four states that previously covered GLP-1s for obesity through Medicaid, California, New Hampshire, Pennsylvania, and South Carolina, have dropped that coverage since late 2025.⁷ Mississippi remains one of 13 state Medicaid programs covering these drugs for weight loss as of January 2026, but the policy exists at the state’s discretion rather than as a federal requirement.

What to Do Next

If you think you qualify, make an appointment with a Medicaid-enrolled prescriber and ask them to submit a prior authorization through MESA. Bring any records that support a qualifying comorbidity if your BMI is in the 25 to 29 range, and expect the office to document a diet and physical activity counseling conversation as part of the request. Plan ahead for the six-month check-in, because staying on Wegovy depends on filled prescriptions and measurable weight loss by that date.

1
Mississippi Division of Medicaid. Mississippi Medicaid Preferred Drug List, January 2026
2
Mississippi Division of Medicaid. Anti-Obesity Select Agents PA Criteria
3
Mississippi Division of Medicaid. Anti-Obesity Select Agents PA Criteria, January 2026
4
Mississippi Division of Medicaid. Anti-Obesity Select Agents PA Criteria, Version 1
5
Mississippi Division of Medicaid. Wegovy in MASH PA Criteria
6
KFF Health News. Mississippi Medicaid GLP-1s Weight Loss Drugs Obesity
7
KFF. Medicaid Coverage of and Spending on GLP-1s